Acadia Pharmaceuticals | ACAD - Current Liabilities

Stock Price
24.13
Daily Change
0.14 0.58%
Monthly
-10.16%
Yearly
23.87%
Q1 Forecast
23.25

Acadia Pharmaceuticals reported $356.58M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
ALKERMES USD 474.36M 31.6M Sep/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Cara Therapeutics USD 10.68M 9.48M Jun/2025
Corcept Therapeutics USD 172.26M 27.6M Sep/2025
Cytokinetics USD 142.14M 11.08M Sep/2025
Eisai JPY 387.67B 9.42B Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
J&J USD 54.13B 3.26B Dec/2025
Moderna USD 1.99B 306M Dec/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
Prothena USD 51.44M 16.37M Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025